SoftBank To Invest $900M In Pacific Biosciences - WSJ

  • SoftBank Group Corp SFTBY will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% stake in PacBio that Softbank amassed almost a month back, worth over $350 million.
  • Last year, PACB was blocked by U.S. antitrust enforcers from merging with Illumina in a $1.2B deal. Illumina paid PacBio a $98 million breakup fee. But under their arrangement, if PacBio raised more than $100 million subsequently, it would owe Illumina $52 million. PacBio will now have to pay that amount.
  • The company recently announced a multi-year collaboration with Invitae Corp (NYSE: NVTA) to begin developing a production-scale high-throughput sequencing platform leveraging PacBio’s HiFi sequencing to expand Invitae’s whole genome testing capabilities.
  • Both companies committed resources to support the development.
  • Price Action: PACB gained 4.45% at $41.3 in premarket trading on the last check Wednesday, while NVTA closed 3.5% higher at $52.6 on Tuesday.
  • Image Courtesy: Wikimedia
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsOfferingsTop StoriesTechGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!